It now requires, for its typical form, the combination of amnesic syndrome of hippocampal type and a pathophysiological AD biomarker, such as cerebrospinal fluid proteins (decreased Aβ42 and increased T-tau and P-tau) or amyloid plaques detected by PET imaging with a specific tracer [5]. This evidence concerns the gene MAPT and Alzheimer disease.